Stocks and Investing
Stocks and Investing
Tue, December 8, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, December 7, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Maintained (BCRX) at Strong Buy with Increased Target to $14 on, Dec 7th, 2020
Andrew Fein of HC Wainwright & Co., Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy with Increased Target from $13 to $14 on, Dec 7th, 2020.
Andrew has made no other calls on BCRX in the last 4 months.
There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- Liisa Bayko of "Evercore ISI Group" Initiated at Buy and Held Target at $12 on, Tuesday, November 24th, 2020
Contributing Sources